ResMed Stock Slides -5.5% With A 6-Day Losing Spree
ResMed (RMD) stock hit day 6 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -5.5% return. The company has lost about $2.2 Bil in value over the last 6 days, with its current market capitalization at about $38 Bil. The stock remains 12.9% above its value at the end of 2024. This compares with year-to-date returns of 17.2% for the S&P 500.
RMD provides medical devices and cloud-based software for healthcare, including remote monitoring and personalized therapy management applications for sleep apnea patients. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell RMD.
A single stock can be risky, but there is a huge value to a broader, diversified approach we take with the Trefis High Quality Portfolio. Separately, consider what the long-term performance for your portfolio could be if you combined 10% commodities, 10% gold, and 2% crypto with equities.
Comparing RMD Stock Returns With The S&P 500
- Buying ADSK at a Discount? You Are Getting Paid to Do It
- What Could Spark the Next Big Move In Lam Research Stock
- Cash Machine Trading Cheap – Shift4 Payments Stock Set to Run?
- Should You Pay Attention To Micron Technology Stock’s Momentum?
- Is Wall Street Underestimating Las Vegas Sands Stock’s Potential?
- With Strong Cash Flow, Chemed Stock Poised to Rise?
The following table summarizes the return for RMD stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | RMD | S&P 500 |
|---|---|---|
| 1D | -1.0% | 0.2% |
| 6D (Current Streak) | -5.5% | 2.3% |
| 1M (21D) | -5.3% | 3.4% |
| 3M (63D) | -7.3% | 8.3% |
| YTD 2025 | 12.9% | 17.2% |
| 2024 | 34.2% | 23.3% |
| 2023 | -16.5% | 24.2% |
| 2022 | -19.5% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: RMD Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 52 S&P constituents with 3 days or more of consecutive gains and 80 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 19 | 46 |
| 4D | 27 | 21 |
| 5D | 1 | 9 |
| 6D | 1 | 2 |
| 7D or more | 4 | 2 |
| Total >=3 D | 52 | 80 |
Key Financials for ResMed (RMD)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $4.7 Bil | $5.1 Bil |
| Operating Income | $1.4 Bil | $1.7 Bil |
| Net Income | $1.0 Bil | $1.4 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ3 | 2025 FQ4 |
|---|---|---|
| Revenues | $1.3 Bil | $1.3 Bil |
| Operating Income | $426.3 Mil | $456.6 Mil |
| Net Income | $365.0 Mil | $379.7 Mil |
The losing streak RMD stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.